Apax Partners Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: London United Kingdom (1969)
Status: No NME R&D (1969)

Organization Overview

First Clinical Trial
None
First Marketed Drug
2007
alprazolam
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (15)

acetaminophen (tylenol) (2011)

alprazolam (2007)

carbinoxamine maleate (clistin) (2008)

clindamycin (cleocin) (2015)

desogestrel (Mercilon) (2011)

dutasteride (avodart) (2015)

ethinyl estradiol (Estinyl) (2010)

felodipine (plendil) (2011)

folic acid (2010)

hydrocodone (hycodan) (2011)

norethindrone (2010)

norgestrel (Ovral) (2011)

oxycodone (oxycontin) (2013)

prednisolone (hydeltra) (2007)

propoxyphene (Darvon) (2009)

Drugs in Phase 4 Trials (3)

Key: Apax Partners (0) Acquired (3)

levofloxacin (levaquin) (1 trial)

oxymetazoline (ocuclear) (1 trial)

solifenacin (vesicare) (1 trial)

Drugs in Phase 2 Trials (5)

Key: Apax Partners (0) Acquired (5)

fluorouracil (efudex) (1 trial)

foxy-5 (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

teriparatide (2 trials)

Drugs in Phase 1 Trials (3)

Key: Apax Partners (0) Acquired (3)

phi-101 (2 trials)

sargramostim (leukine) (1 trial)

somatropin (protropin) (1 trial)

Drugs in Other Trials (1)

Key: Apax Partners (0) Acquired (1)

lidocaine (xylocaine) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 10
  • # of Trial APIs: 12